Literature DB >> 2004849

Increasing incidence of cancers associated with the human immunodeficiency virus epidemic.

C S Rabkin1, R J Biggar, J W Horm.   

Abstract

We examined data from San Francisco and other areas participating in the Surveillance, Epidemiology, and End Results (SEER) Program to determine the effect of the human immunodeficiency virus (HIV) epidemic on cancer incidence between 1973 and 1987. In this period, non-Hodgkin's lymphoma incidence has increased over 10-fold and Kaposi's sarcoma incidence has increased over 5000-fold in single San Francisco men 20 to 49 years of age. Increases in non-Hodgkin's lymphoma have been restricted to high-grade and diffuse large-cell (intermediate-grade) histological types. With the exceptions of non-Hodgkin's lymphoma and Kaposi's sarcoma, no other tumor has significantly increased in incidence. During 1987, we estimate that HIV-seropositive men in San Francisco had a 0.47% risk of developing non-Hodgkin's lymphoma and a 1.6% risk of developing Kaposi's sarcoma. The relative risks for non-Hodgkin's lymphoma and Kaposi's sarcoma associated with HIV infection were 104 and 40,000, respectively. For 1987, HIV was associated with 14% of all reported cancers (except non-melanoma skin cancer) in men aged 20 to 49. We expect that 1,890 to 2,730 excess cases of non-Hodgkin's lymphoma and 6,490 to 8,320 excess cases of Kaposi's sarcoma will occur in the United States in 1990.

Entities:  

Mesh:

Year:  1991        PMID: 2004849     DOI: 10.1002/ijc.2910470511

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Natural history of primary Epstein-Barr virus infection in children of mothers infected with human immunodeficiency virus type 1.

Authors:  H Jenson; K McIntosh; J Pitt; S Husak; M Tan; Y Bryson; K Easley; W Shearer
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

2.  Non-acquired immune deficiency syndrome-defining malignancies in a hospital-based cohort of human immunodeficiency virus-infected patients: Bordeaux, France, 1985-1991. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

Authors:  M Hajjar; D Lacoste; G Brossard; P Morlat; M Dupon; L R Salmi; F Dabis
Journal:  J Natl Cancer Inst       Date:  1992-10-21       Impact factor: 13.506

3.  Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma.

Authors:  Richard F Little; James M Pluda; Kathleen M Wyvill; Isaac R Rodriguez-Chavez; Giovanna Tosato; Andrew T Catanzaro; Seth M Steinberg; Robert Yarchoan
Journal:  Blood       Date:  2006-02-28       Impact factor: 22.113

Review 4.  HIV-associated Kaposi sarcoma and related diseases.

Authors:  Priscila H Gonçalves; Thomas S Uldrick; Robert Yarchoan
Journal:  AIDS       Date:  2017-09-10       Impact factor: 4.177

5.  Association between human immunodeficiency virus type 1 infection and cancer in the black population of Johannesburg and Soweto, South Africa.

Authors:  F Sitas; W R Bezwoda; V Levin; P Ruff; M C Kew; M J Hale; H Carrara; V Beral; G Fleming; R Odes; A Weaving
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Antiproliferative effect of retinoid compounds on Kaposi's sarcoma cells.

Authors:  J Corbeil; E Rapaport; D D Richman; D J Looney
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

Review 7.  Malignant tumours in patients with HIV infection.

Authors:  U Tirelli; S Franceschi; A Carbone
Journal:  BMJ       Date:  1994-04-30

8.  Assessing the relationship between marital status and cancer incidence: methodologic considerations.

Authors:  K Zhu; N S Weiss; S M Schwartz; J R Daling
Journal:  Cancer Causes Control       Date:  1994-01       Impact factor: 2.506

9.  Site specific target binding controls RNA cleavage efficiency by the Kaposi's sarcoma-associated herpesvirus endonuclease SOX.

Authors:  Aaron S Mendez; Carolin Vogt; Jens Bohne; Britt A Glaunsinger
Journal:  Nucleic Acids Res       Date:  2018-12-14       Impact factor: 16.971

10.  Have increases in solar ultraviolet exposure contributed to the rise in incidence of non-Hodgkin's lymphoma?

Authors:  A J McMichael; G G Giles
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.